USFDA approves ANDA filed by Granules India’s arm for Potassium Chloride Oral Solution

01 Feb 2021 Evaluate

The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly owned foreign subsidiary of Granules India, for Potassium Chloride Oral Solution USP, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%). It is bioequivalent to the reference listed drug product (RLD), Potassium Chloride Oral Solution, 20 mEq/15 mL (10%) and 40 mEq/15 mL (20%), of Genus Lifesciences, Inc. The product would be available in bottle of 473 ml and is expected to be launched shortly.

Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. Potassium Chloride Oral solution products had U.S. sales of approximately $75 million for the most recent twelve months ending in November 2020 according to IQVIA Health. Granules now has a total of 36 ANDA approvals from US FDA (35 Final approvals and 1 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

608.80 -7.95 (-1.29%)
08-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.30
Dr. Reddys Lab 1370.60
Cipla 1495.05
Lupin 2252.40
Zydus Lifesciences 981.55
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.